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Amiodarone (AMD) is a potent antiarrhythmic drug with high efficacy for treating
atrial fibrillation and tachycardia. The pharmacologic profile of AMD is complex. AMD
possesses biophysical characteristics of all of class I, II, III, and IV agents. Despite its
adverse side effects, AMD remains the most commonly prescribed antiarrhythmic drug.
AMD was described to prolong the QT interval and can lead to torsades de pointes.
Our goal was to study the effects of AMD on peak and late sodium currents (INa,P
and INa,L) and determine whether these effects change as AMD is metabolized into
N-desethylamiodarone (DES). We hypothesized that AMD and DES block both INa,P and
INa,L with similar profiles due to structural similarities. Given the inherent small amounts
of INa,L in NaV1.5, we screened AMD and DES against the Long QT-3-causing mutation,
1KPQ, to better detect any drug-mediated effect on INa,L. Our results show that AMD
and DES do not affect WT or1KPQ activation; however, both drugs altered the apparent
valence of steady-state fast-inactivation. In addition, AMD and DES preferentially block
1KPQ peak conductance compared to WT. Both compounds significantly increase INa,L
and window currents. We conclude that both compounds have pro-arrhythmic effects
on NaV1.5, especially 1KPQ; however, DES seems to have a greater pro-arrhythmic
effect than AMD.
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INTRODUCTION
In the 1960s, an iodine-containing benzofuran compound called amiodarone (AMD) was
developed as a therapeutic vasodilator (Phillips and Bauman, 1995). Decades of research and
clinical trials have shown the effects of AMD in a range of organ systems. AMD slowly became
a widely used antiarrhythmic drug, with a high efficacy for treating conditions including atrial
fibrillation and tachycardia (Pollak, 1998). The pharmacologic profile of this drug is complex.
Although AMD has been classified primarily as a class III antiarrhythmic drug, it also has
biophysical characteristics of class I, II, and IV agents in that it blocks L-type calcium, potassium,
and sodium currents (Singh and Vaughan Williams, 1970; Kodama et al., 1997; Nattel and Singh,
1999; Wu et al., 2008). AMD is the most commonly prescribed antiarrhythmic drug despite its
potentially serious side effects, including adverse effects on thyroid glands, the pulmonary system,
and the liver (Danzi and Klein, 2015).
In experimental cardiac preparations, the use of AMD is associated with prolongation of the
QT interval and action potential duration (APD). These events may lead to torsades de pointes
(Tarapues et al., 2014). AMD has a higher selectivity for the potassium and sodium channels that
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are expressed in atrial as opposed to ventricular myocytes (Suzuki
et al., 2013). The atrial selectivity of sodium channel block may
contribute to the treatment of atrial fibrillation (Antzelevitch
and Burashnikov, 2009; Burashnikov and Antzelevitch, 2013).
However, AMD’s potency to prolong the QT interval has led to
its prohibition in patients with Long-QT Syndrome (Digby et al.,
2011; Franz et al., 2014).
Long-term treatments with AMD is suggested to induce
remodeling of ion-channel expression in a dose-dependent
manner, leading to electrophysiological variations. Therefore, in
addition to directly affecting membrane proteins, AMD also
modifies the levels of ion-channel transcripts (Le Bouter et al.,
2004).
Although several Cytochrome P450 (CYP) subtypes may
contribute to metabolism of any given compound, the primary
enzymes involved in the AMD metabolism are CYP3A4 and
CYP2C8 (Ohyama et al., 2000; Zahno et al., 2011). AMD has a
relatively long half-life of 40–50 days (Zipes et al., 1984). The
full metabolism of AMD gives rise to 22 phase I and 11 phase II
products (Deng et al., 2011). AMD’s most prominent metabolite
is produced as a result of a N-deethylation reaction catalyzed
by CYP3A4, producing DES, which is a pharmacologically active
compound (Deng et al., 2011).
In a classic study conducted by Pallandi and Campbell (1987)
on guinea-pig ventricular myocardium, it was determined that
at clinically relevant levels, AMD and DES exhibit both class I
and class III effects. The class I effects (on sodium channels) are
rate dependent, which in conjunction with the class III effects
(on potassium channels) may increase APD and reduce Vmax
(Pallandi and Campbell, 1987).
Despite the potency of AMD as an antiarrhythmic agent and
the already existing body of knowledge, its effects on sodium
channels are still poorly understood. We sought to study the
effects of AMD on peak and late sodium currents (INa,P and
INa,L), and determine whether these effects change as AMD
metabolizes into DES. We hypothesized that both AMD and
DES block INa,P and INa,L with similar profiles due to their
structural similarities. Given the low amplitude of INa,L in
Nav1.5, we used the LQT-3 mutation, 1KPQ, to increase INa,L
and thus better detect potential drug-mediated effect on INa,L.
The mutant phenotype associated with 1KPQ is manifested in
the presence of large INa,L due to the deletion of three amino
acids (Lysine, Proline, Glutamine) in the linker region between
domains III and IV in NaV1.5 (Wang et al., 1995). This is
a hot-spot region in NaV1.5 since it elicits fast-inactivation
(Chandra et al., 1998). We report that AMD and DES have
similar effects on the voltage-dependence of fast-inactivation




Chinese hamster ovary (CHO) cells were transiently transfected
with cDNA encoding either wild-type or the1KPQ mutant form
FIGURE 1 | (A–D) Show the voltage dependence of activation as normalized conductance plotted against membrane potential. The black curves represent the WT
Nav1.5 or 1KPQ conductance with no drug perfusion, the orange curves represent Nav1.5 or 1KPQ conductance after either 0.5 or 2.5 µM AMD perfusion, and
the blue curves represent Nav1.5 or 1KPQ conductance after either 0.5 or 2.5 µM DES perfusion.
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of NaV1.5. Transfection was done according to the PolyFect
transfection protocol. After each set of transfections, a minimum
of 8 h incubation was allowed before platting. Dr. Robert
Kass generously provided SCN5A cDNA encoding the 1KPQ
mutation.
Electrophysiology
Whole-cell patch clamp recordings were performed in an
extracellular solution containing (in mM): 140 NaCl, 4 KCl,
2 CaCl2, 1 MgCl2, 10 HEPES. Solutions were adjusted to
pH 7.4 with CsOH. Pipettes were filled with intracellular
solution, containing (in mM): 120 CsF, 20 CsCl, 10 NaCl,
10 HEPES, pH 7.4. All recordings were made using an
EPC-9 patch-clamp amplifier (HEKA Elektronik, Lambrecht,
Germany) digitized at 20 kHz via an ITC-16 interface (Instrutech,
Great Neck, NY, USA). Voltage clamping and data acquisition
were controlled using PatchMaster/FitMaster software (HEKA
Elektronik, Lambrecht, Germany) running on an Apple iMac.
Current was low-pass-filtered at 5 kHz. Leak subtraction was
performed automatically by software using a P/4 procedure
following the test pulse. Gigaohm seals were allowed to stabilize
in the on-cell configuration for 1 min prior to establishing
the whole-cell configuration. Series resistance was less than
5 M for all recordings. Series resistance compensation up
to 80% was used when necessary. All data were acquired at
least 5 min after attaining the whole-cell configuration, and
cells were allowed to incubate 5 min after drug application
prior to data collection. Before each protocol, the membrane
potential was hyperpolarized to −130 mV to insure complete
removal of both fast-inactivation and slow-inactivation. Leakage
and capacitive currents were subtracted with a P/4 protocol.
All experiments were conducted at room temperature at
22◦C.
Analysis
Analysis and graphing were done using FitMaster software
(HEKA Elektronik) and Igor Pro (Wavemetrics, LakeOswego,
OR, USA) with statistical information derived using JMP
TABLE 1 | Steady-state activation.
GV – V1/2 (mV) GV – z (slope) n
Wild-type
NaV1.5
Control −35.5 ± 1.63 3.79 ± 0.29 20
AMD 0.5 µM −45.7 ± 4.42 3.91 ± 0.69 4
AMD 2.5 µM −36.1 ± 1.45 3.54 ± 0.15 4
DES 0.5 µM −35.5 ± 3.57 3.25 ± 0.54 7
DES 2.5 µM −32.4 ± 1.87 2.67 ± 0.40 5
1KPQ
NaV1.5
Control −33.6 ± 2.35 3.25 ± 0.34 20
AMD 0.5 µM −34.8 ± 2.75 2.29 ± 0.24 5
AMD 2.5 µM −35.1 ± 4.61 2.63 ± 0.26 6
DES 0.5 µM −31.1 ± 5.34 2.26 ± 0.16 4
DES 2.5 µM −31.1 ± 3.10 2.66 ± 0.53 4
statistical software version 11. All data acquisition and analysis
programs were run on an Apple iMac (Apple Computer). A two-
way analysis of variance (ANOVA) was used to compare the
means responses [activation, peak current block, steady-state
fast-inactivation (SSFI), late currents, and window currents]
between channel variant, and compound. Channel variant,
compound and the way interaction involving the two were
considered to be fixed effects in the model. Channel variant had
two levels (WT, 1KPQ) and compound had six levels (0, 0.5, and
2.5 µM AMD and DES). Post hoc tests using the Tukey Kramer
adjustment were used to compare mean responses between pairs
of channel variant and/or compounds. A level of significance
α = 0.05 was used in all overall post hoc tests, and effects
with p-values less then 0.05 were considered to be statistically
FIGURE 2 | Current amplitude plotted versus time duration. The traces
show the variation in current levels before and after AMD and DES perfusion.
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significant. All values reported are given as mean ± standard
error of means for n cells.
Activation Protocols
To determine the voltage dependence of activation, we measured
the peak current amplitude at test pulse potentials ranging from
−100 to +80 mV in increments of +10 mV for 20 ms. Channel
conductance (G) was calculated from peak INa:
GNa = INa/V− ENa
where GNa is conductance, INa is peak sodium current in response
to the command potential V, and ENa is the Nernst equilibrium
potential. Calculated values for conductance were fit with the
Boltzmann equation:
G/Gmax = 1/(1+ exp[−ze0[Vm − V1/2]/kT])
where G/Gmax is normalized conductance amplitude, Vm is the
command potential, z is the apparent valence, e0 is the elementary
charge, V1/2 is the midpoint voltage, k is the Boltzmann constant,
and T is temperature in ◦K.
Steady-State Fast-Inactivation Protocols
The voltage-dependence of fast-inactivation was measured by
preconditioning the channels to a hyperpolarizing potential of
TABLE 2 | Peak INa block.
Peak INa block n
Wild-type
zNaV1.5
AMD 0.5 µM 0.05 ± 0.11 3
AMD 2.5 µM 0.14 ± 0.12 6
DES 0.5 µM 0.32 ± 0.05 7
DES 2.5 µM 0.12 ± 0.13 6
1KPQ
NaV1.5
AMD 0.5 µM 0.39 ± 0.12 6
AMD 2.5 µM 0.38 ± 0.28 4
DES 0.5 µM 0.28 ± 0.04 4
DES 2.5 µM 0.55 ± 0.12 6
−130 mV and then eliciting pre-pulse potentials that ranged from
−170 to +10 mV in increments of 10 mV for 500 ms, followed
by a 10 ms test pulse during which the voltage was stepped to
0 mV. Normalized current amplitude as a function of voltage was
fit using the Boltzmann equation:
I/Imax = 1/(1+ exp(−ze0(VM − V1/2)/kT)
where Imax is the maximum test pulse current amplitude.
FIGURE 3 | (A–D) Show the voltage dependence of steady-state fast-inactivation as normalized current plotted against membrane potential. The black curves
represent the WT Nav1.5 or 1KPQ SSFI with no drug perfusion, the orange curves represent Nav1.5 or 1KPQ SSFI after either 0.5 or 2.5 µM AMD perfusion, and
the blue curves represent Nav1.5 or 1KPQ SSFI after either 0.5 or 2.5 µM DES perfusion.
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Window Current Measurements
Window currents were measured by maintaining the voltage at
−130 mV for 1 s. Then, the voltage was ramped to 20 mV for
20 ms, at a rate of 0.3 mV/ms. The channels were then recovered
from inactivation at the voltage of−130 mV for 20 ms.
Drug Preparation
We sought to study the effects of AMD and DES on cardiac
voltage-gated sodium channels using their therapeutic serum
concentrations which, for both compounds, is 2.5 µM (Sheldon
et al., 1989). However, xenobiotic concentrations decrease over
time; therefore, to assess the effects of these reductions, our
experiments were also conducted at 0.5 µM AMD and DES.
To ensure no run-down of sodium currents is taking place,
electrophysiological recordings were taken on average 3–5 min
after AMD or DES perfusion, until current levels were stabilized.
Simulations
Action potentials were simulated in OpenCell (Physiome Project)
with the 2004 Hund-Rudy Canine ventricular cell model (Rate
Dependence and Regulation of Action Potential and Calcium
Transient in a Canine Cardiac Ventricular Cell Model, Hund
and Rudy, 2004. http://models.cellml.org/exposure/f4b7120a
a512c7f5e7a0664abcee3e8b/hund_rudy_2004_b.cellml/view 6.33
pm 12th January 2016 CellML author(s): Catherine Lloyd) (Hund
and Rudy, 2004; Lloyd et al., 2008).
RESULTS
Activation
We examined the effects of AMD and DES on activation
in NaV1.5 and 1KPQ channels. Figure 1 shows normalized
conductance plotted as a function of membrane potential under
control solutions (black curves with filled circles), in AMD
solutions (orange curves with filled circles), and DES solutions
(blue curves with filled circles) in WT and 1KPQ NaV1.5
channels. AMD and DES cause no significant effects on the
TABLE 3 | Steady-state fast-inactivation.
SSFI – V1/2 (mV) SSFI – z (slope) n
Wild-type
NaV1.5
Control −83.0 ± 1.82 −2.68 ± 0.10 20
AMD 0.5 µM −89.1 ± 6.04 −2.81 ± 0.33 4
AMD 2.5 µM −87.4 ± 3.79 −2.36 ± 0.15 7
DES 0.5 µM −89.5 ± 4.38 −2.19 ± 0.12 7
DES 2.5 µM −88.4 ± 3.00 −1.89 ± 0.14 5
1KPQ
NaV1.5
Control −92.3 ± 3.06 −2.79 ± 0.15 20
AMD 0.5 µM −107.3 ± 3.69 −2.08 ± 0.16 6
AMD 2.5 µM −94.9 ± 5.21 −2.22 ± 0.19 5
DES 0.5 µM −100.3 ± 4.86 −2.74 ± 0.34 4
DES 2.5 µM −107.8 ± 5.24 −2.38 ± 0.21 5
voltage dependence of activation. There were no significant shifts
in the midpoint or apparent valence at either 0.5 or 2.5 µM of
AMD or DES in either NaV1.5 or 1KPQ (p > 0.05; Table 1).
Current traces from the eight experimental conditions (before
and after AMD or DES perfusion) are shown in (Figure 2).
Peak Current Block
Amiodarone is a sodium channel blocker. To determine whether
there is a difference between AMD and DES in their ability to
block INa, we compared the peak current in each channel variant
before and after the perfusion of either compound at one of the
noted concentrations. Although current block was seen across all
conditions, there was a significant mutant effect, indicating that
both the mother compound, AMD, and its metabolite, DES, block
FIGURE 4 | Fast-inactivation traces. Traces show the variation in current
levels before and after AMD and DES perfusion.
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1KPQ more than they block NaV1.5 (p < 0.05; Table 2). The
largest block was observed in 1KPQ mutants at 2.5 µM DES
(Table 2).
Steady-State Fast-Inactivation
To quantify the effects of each compound at 0.5 and 2.5 µM
on fast-inactivation, we compared the apparent valence (z) and
midpoint (V1/2) from Boltzmann fits to SSFI data for NaV1.5
(Figures 3A,B) and 1KPQ (Figures 3C,D). Normalized current
amplitudes were plotted as a function of pre-pulse potential
(Figure 3). The apparent valence of SSFI of 1KPQ (2.79 ± 0.15)
was greater than that of WT NaV1.5 (2.68 ± 0.10). AMD and
DES at 0.5 and 2.5 µM significantly reduced the apparent valence
of SSFI in both NaV1.5 and 1KPQ (p < 0.05; Table 3). The
V1/2 of1KPQ was significantly hyperpolarized compared to WT
(p< 0.05); however, there were no significant shifts in the V1/2 of
either channel variant with AMD or DES at either concentration
(p > 0.05; Table 3). Representative traces are shown in
(Figure 4).
Late Sodium Currents
The presence of INa,L is an indicator of destabilized fast-
inactivation. We show representative normalized current
traces of INa,L for the two channel variants across all
conditions (Figure 5). Although, both compounds appear
to have statistically significant effects on elevating INa,L levels
(p < 0.01), the most prominent INa,L increase was seen upon
the perfusion of 2.5 µM DES on 1KPQ (Figure 6A; Table 4).
Therefore, therapeutic levels of DES potently further destabilize
fast-inactivation in 1KPQ mutants.
Sodium Window Currents
Changes in both steady-state activation and fast-inactivation
can lead to differences in the window current. Representative
normalized traces of sodium window currents from all conditions
are shown in (Figure 7). Similar to INa,L, there was an significant
compound effect on the sodium window currents (p < 0.05),
where the greatest effect was seen in 1KPQ at 2.5 µM DES
(Figure 6B; Table 5).
FIGURE 5 | Representative normalized current traces of INaL. (A–H) Each panel shows the INaL in NaV1.5 or 1KPQ before and after the perfusion of either
0.5 or 2.5 µM AMD or DES. Black curves represent control (0 µM drug solution), orange curves represent AMD at either 0.5 or 2.5 µM, and blue curves represent
DES at either 0.5 or 2.5 µM.
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FIGURE 6 | (A) Shows the percentage of persistent sodium currents in either WT Nav1.5 or 1KPQ channels after the perfusion of 0, 0.5, or 2.5 µM AMD (light or
dark orange) or DES (light or dark blue). (B) Shows the percentage of window sodium currents in either WT Nav1.5 or 1KPQ channels after the perfusion of 0, 0.5,
or 2.5 µM AMD (light or dark orange) or DES (light or dark blue).
Action Potential Modeling
The duration of action potentials plays a fundamental role
in the functioning of cardiac myocytes. The alteration of any
contributors in action potential generation and maintenance






Control 0.88 ± 0.16 23
AMD 0.5 µM 1.23 ± 0.41 6
AMD 2.5 µM 2.39 ± 0.59 6
DES 0.5 µM 2.16 ± 0.83 6
DES 2.5 µM 2.84 ± 0.59 5
1KPQ
NaV1.5
Control 2.79 ± 0.55 18
AMD 0.5 µM 2.89 ± 1.35 6
AMD 2.5 µM 2.62 ± 0.73 6
DES 0.5 µM 3.62 ± 0.79 5
DES 2.5 µM 12.6 ± 3.18 4
could lead to detrimental effects such as life-threatening
arrhythmias. In order to determine whether the observed
compound-mediated fast-inactivation destabilization can lead
to pro-arrhythmogenicity, we used the Hund-Rudy Canine
model to simulate a cardiac action potential (Figure 8). The
simulation results indicate that the extent of action potential
prolongation is consistent with our experimental data showing
compound-mediated exacerbation in INa,L. As expected, the
APD of 1KPQ was longer than NaV1.5, hence the LQT
phenotype. Furthermore, the model suggests that the biggest pro-
arrhythmogenic effect occurs at 2.5 µM DES in 1KPQ mutants
(Figure 8; Table 6).
DISCUSSION
Since its development, the use of AMD as a therapeutic
has fluctuated due to occasional reports of toxicity in some
individuals. These safety issues have resulted in AMD being
regarded as a dangerous drug; however, the efficacy of this drug
against certain conditions, such as atrial fibrillation, is well-
established.
We performed the first detailed study on the effects of AMD
on cardiac voltage-gated sodium channels. We included DES, a
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FIGURE 7 | Representative sodium window currents. (A–H) Each panel shows the window currents in NaV1.5 or 1KPQ before and after the perfusion of either
0.5 or 2.5 µM AMD or DES. Black curves represent control (0 µM drug solution), orange curves represent AMD at either 0.5 or 2.5 µM, and blue curves represent
DES at either 0.5 or 2.5 µM.
physiologically active metabolite of AMD, into our study, and
compared the effects of AMD and DES on biophysical properties
in WT NaV1.5 and 1KPQ, a channel variant with an exaggerated
late current. Neither AMD nor DES affect the voltage dependence
of activation or SSFI. However, a decrease in the apparent valence
in SSFI of both channels suggests that the compounds reduce the
NaV1.5 and 1KPQ charge sensitivities.
Although AMD has been recognized as a sodium channel
blocker, DES has not been fully characterized with respect to
its effects on sodium channels. Here, we show that DES also
blocks sodium channels. Interestingly, both compounds have
a significant preference in blocking 1KPQ compared to WT
NaV1.5.
Our results indicate that DES significantly increases both INa,L
and window currents in 1KPQ mutants. Given that the presence
of INa,L is a manifestation of the failure to fast-inactivate, we
conclude that DES further disrupts 1KPQ fast-inactivation.
In an earlier study, Maltsev et al. (2001) performed
electrophysiological studies on cardiac cells isolated from
failing human hearts. They concluded that AMD blocks late
sodium currents in these cells. However, within the same
study they mentioned that the interpretation of their results
is rather complicated due to the INa,L density variations in
the cardiomyocytes from different patients (Maltsev et al.,
2001). These variations point to the differences in the genetic
background present in isolated myocytes, which may have led
to the observed results in that study. In order to reduce the
confounding effects of the rather complex genetic background
in human myocytes, we performed our studies in the simpler
CHO cells. This allowed us to understand the biophysics of
Frontiers in Pharmacology | www.frontiersin.org 8 March 2016 | Volume 7 | Article 39
fphar-07-00039 March 1, 2016 Time: 17:17 # 9
Ghovanloo et al. AMD/DES Effects on NaV1.5




Control 1.77 ± 0.25 19
AMD 0.5 µM 2.51 ± 0.62 5
AMD 2.5 µM 3.10 ± 1.02 4
DES 0.5 µM 1.28 ± 0.57 6
DES 2.5 µM 3.52 ± 0.91 4
1KPQ
NaV1.5
Control 4.30 ± 0.47 22
AMD 0.5 µM 1.84 ± 0.82 5
AMD 2.5 µM 3.39 ± 0.69 5
DES 0.5 µM 6.27 ± 1.28 6
DES 2.5 µM 7.18 ± 1.45 5
the interactions between AMD/DES and NaV1.5/1KPQ on a
fundamental level, and then apply that information to a generic
myocyte action potential model using computer simulations.
In another study conducted by Wu et al. (2008) attempting
to characterize AMD, sea anemone toxin II (ATX-II) was used
to induce INa,L in NaV1.5. This study concluded that ATX-II-
mediated INa,L is blocked by AMD (Wu et al., 2008). These
results led us to initially hypothesize that AMD and DES would
block both INa,L and INa,P; however, ATX-II is also a chemical
agent that interacts with sodium channels. To eliminate inter-
compound interactions between ATX-II and AMD or DES, we
used 1KPQ. The pro-arrhythmic effects of these compounds on
INa,L were, particularly notable. Mutational studies in NaV1.2
indicate that ATX-II tends to interact close to the glutamic acid
residue at position 1613 on the DIVS3-S4 extracellular loop
(Rogers et al., 1996). Considering AMD and DES were perfused
on the extracellular side of the channels in our experiments, along
with previous findings in NaV1.2, our contradictory results to Wu
et al. (2008) seem justified. We predict that the mode of action
of AMD may involve interactions with DIVS3-S4 of the sodium
channel. This would indicate that AMD outcompetes ATX-II for
binding sites on the sodium channel. This hypothesis may explain
the decrease in INa,L in ATX-II-treated channels; however, this
hypothesis needs to be tested in future studies.
It is well-known that the prolongation of the QT interval
on the electrocardiogram is a prominent risk factor for
arrhythmias, which may lead to sudden death. There are
many pathophysiological mechanisms that may underlie this
prolongation; however, those that increase the APD are perhaps
most common. Sodium channels are a key contributor to action
potential generation and propagation (Catterall et al., 2005);
therefore, disrupting these channels’ ability to fast-inactivate
could result in the elongation of the APD, which could prolong
the QT interval leading to arrhythmogenicity. According to
TABLE 6 | Action potential duration.




AMD 0.5 µM 204.4 −70.0
AMD 2.5 µM 224.3 −70.0
DES 0.5 µM 221.4 −70.0




AMD 0.5 µM 235.2 −70.0
AMD 2.5 µM 230.2 −70.0
DES 0.5 µM 247.8 −70.0
DES 2.5 µM 496.1 −70.0
FIGURE 8 | Action potential model simulation. (A) Shows the simulations belonging to WT Nav1.5, where the black curve represents control, light and dark
orange curves represent AMD perfusion at 0.5 and 2.5 µM, respectively, and light and dark blue curves represent DES perfusion at 0.5 and 2.5 µM, respectively.
(B) Shows the simulations belonging to 1KPQ, where the black curve represents control, light and dark orange curves represent AMD perfusion at 0.5 and 2.5 µM,
respectively, and light and dark blue curves represent DES perfusion at 0.5 and 2.5 µM, respectively.
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our simulation results, AMD and DES indeed increase APD
in myocytes. Thus, we conclude that these compounds could
contribute to pro- arrhythmogenicity.
Despite the possibility of having pro-arrhythmic effects, our
findings suggest that AMD and DES can also have an anti-
arrhythmic effect in that they block INa,P. This mode of action is
not unique to these compounds. Similar to AMD and DES, Wang
et al. (1990) have shown that a compound called DPI 201-106
slows cardiac sodium channel inactivation, followed by blocking
peak inward sodium currents.
N-desethylamiodarone seems to be a more potent pro-
arrhythmic agent than the AMD from which it is metabolized.
Since the LQT diagnosis is identified with an abnormally long QT
interval, the use of AMD in a patient with this condition may be
lethal. Therefore, our findings are a further validation for caution
in the use of AMD in LQT patients, and specifically in those with
the 1KPQ mutation. Moreover, although AMD and DES have
similar chemical structures, as we have shown, their effects on
ionic sodium currents are not identical. Thus, we predict further
characterization of AMD’s long list of metabolites may uncover
substantial clinically relevant information.
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